CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 25 target
Drug / intervention
Panitumumab-IRDye800drug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
  • ✓Scheduled to undergo surgical resection with curative intent for squamous cell carcinoma
  • ✓Any T stage, any subsite within the head and neck, including recurrent disease or new primary
  • ✓Age ≥ 18 years
Key exclusion· 9
  • ✕Received investigational drug within 30 days prior to first dose
  • ✕MI, CVA, or uncontrolled CHF within 6 months prior to enrollment
  • ✕History of infusion reactions to any monoclonal antibody therapies
  • ✕Pregnant or breast-feeding

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04511078
NCT04511078Phase 2RecruitingOn TrackUpdated 6mo ago
Long Recruiting
CompareCT.gov

Phase II Open-Label Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures

University of Alabama at Birmingham·interventional·Posted Aug 12, 2020·Updated Dec 24, 2025

In Brief

A Phase 2 clinical trial evaluating Panitumumab-IRDye800 for Head and Neck Cancer. Currently recruiting, targeting 25 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2Recruiting
20212022202320242025202620272028202920302031
First PostedAug 12, 2020
Enrollment StartApr 2, 2021
Primary CompletionDec 31, 2030
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 5.9 years agoPrimary completion in 4.5 years

Interventions

Panitumumab-IRDye800drug

single dose infusion of panitumumab-IRDye800CW